Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · March 23, 2022

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin vs Gemcitabine and Cisplatin as Perioperative Chemotherapy for NMIBC

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial
J. Clin. Oncol 2022 Mar 07;[EPub Ahead of Print], C Pfister, G Gravis, A Fléchon, C Chevreau, H Mahammedi, B Laguerre, A Guillot, F Joly, M Soulié, Y Allory, V Harter, S Culine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading